This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): simvastatin, Lipovas, Ripobasu (Japan)
Description: The active ingredient of Zocor, Simvastatin, inhibits HMG-CoA reductase, an enzyme required for the synthesis of cholesterol. Zocor has been shown to reduce the concentrations of both normal and elevated low density lipoprotein cholesterol (LDL-C).
Deal Structure: In July 2011, Merck and Simcere Pharmaceutical announced the signing of a framework agreement to establish a joint venture focused on serving China's rapidly expanding health care needs. Specifically, in the area of cardiovascular disease, the partnership will offer a combined portfolio of selected medicines from both companies, including ZOCOR (simvastatin), COZAAR (losartan) and RENITEC (enalapril) by Merck/MSD, and XINTA (levamlodipine) and SHUFUTAN (rosuvastatin) by Simcere. In the metabolic disease area, the partnership will work to maximize access in China to sitagliptin.
In October 2011, MSD and Mylan Pharmaceuticals announced the termination of the collaboration agreement for the promotion of Ripobasu (simvastatin) and Renibesu (enalapril maleate).
Additional information available to subscribers only: